

AMENDMENT NO.1 TO THE INVESTIGATOR-INITIATED RESEARCH AGREEMENT dated 05.09.2019 followed by the ASSIGNMENT AND ASSUMPTION OF INVESTIGATOR-INITIATED RESEARCH AGREEMENT dated 05.10.2020 (hereinafter the "Amendment")

concluded between the following contracting parties:

Sanofi s.r.o.

Registered office: Generála Píky 430/26, Dejvice, 160 00 Praha 6, Czech Republic

Represented by: Petr Novak

Id. No.: 44848200

Tax number: CZ44848200

Registered in the Commercial Register maintained with the Municipal Court in Prague, file number: C 5968

Bank details: Citibank Europe plc, organizační složka
Bucharova 2641/14, 158 02 Prague 5, Czech Republic
Account No. 2015410204/2600
IBAN: CZ54 2600 0000 0020 1541 0204
SWIFT: CITICZPX

(hereinafter the „**Sanofi**")

and

Institute for Clinical and Experimental Medicine

Registered office: Vídeňská 1958/9, 14021 Prague 4, Czech Republic

Represented by: Ing. Helena Rögnerová

Id. No.: 00023001

Tax number: CZ00023001

Registered as a state contribution organization, charter of the Ministry of Health of the Czech Republic, file number No. 17268-II/2012 dated 29 May 2012

Banking details: Česká národní banka, Na Příkopě 28, 115 03 Praha 1

Account no.: 34833-42334041/0710
IBAN: CZ29 0710 0348 3300 4233 4041
BIC: CNBACZPP

(Hereinafter the „**IKEM**")




And

Registered office: EMMES BIOPHARMA GLOBAL s. r. o., (formerly NEOX s.r.o., which company was incorporated by Emmes Biopharma Global s.r.o. with the consequent transfer to the latter of all contractual agreements to which Neox was a party), Prague 1, V Jámě 699/1, 110 00 Prague 1, the Czech Republic

Represented by: Pavel Marek, MD, its executive manager

Id. No.:	62917927
Tax number:	CZ-62917927
Registered in the Commercial Register maintained by Municipal Court in Prague, Part C, File number 35823	
Banking details:	Komerční banka, a.s.
Account no.:	43-7569220237/0100
IBAN CZ9001000000437569220237	
SWIFT: KOMBCZPP	
(Hereinafter the „CRO”)	
(Sanofi, IKEM and CRO hereinafter jointly the “Parties”)	
<p style="text-align: center;">I. Changes of the Agreement</p>	
<p>1) The Investigator-Initiated Research Agreement was concluded on 5th of September 2019 (hereinafter the “Agreement”). The Agreement has been followed by the Assignment and Assumption of Investigator-Initiated Research Agreement dated 05.10.2020. The Agreement shall be amended and/or supplemented by this Amendment as follows.</p>	
<p>2) Article 4 of the Agreement is being amended by adding additional sentence of the following wording:</p> <p><i>„Any non-procedural pass-through expenses will increase the amount of funding only if pre-approved by Sanofi, in the amount actually incurred and only if incurred due to the necessary support of the Study. The maximum amount of all such pass-through expenses in aggregate will not exceed 1% of the initial amount of funding (\$ 963,050.20 USD), with no mark-up in cost. To request payment of these costs, entitled Party will submit detailed back-up documentation or receipts sufficient to support pass-through expenses. Payments of such expenses will be made upon the provided invoice.”</i></p>	
<p style="text-align: center;">II. Other provisions</p>	
<p>1) Other provisions of the Agreement remain unaffected by this Amendment.</p>	
<p>2) This Amendment has been executed in three counterparts as originals, of which each contracting Party shall receive one counterpart. If this Amendment is signed electronically (by recognized electronic signature), it shall be executed in one identical copy signed electronically by the parties.</p>	
<p>3) This Amendment becomes valid as of the date of its signatures by all contracting Parties.</p>	
<p>4) This Amendment is subject to publication in the Agreement Register; therefore this Amendment shall become effective in the date of its publication in the Agreement Register based on Act.No.340/2015 Collections of Laws of the Czech Republic on Agreement Register as</p>	

amended. Parties acknowledge and agree that IKEM shall publish this Amendment in the Agreement Register and shall publish only information required by law.

In [•] on [•]	In [•] on [•]	In [•] on [•]
		<i>27.11.2017</i> 
Sanofi s.r.o.	Institute for Clinical and Experimental Medicine	EMMES BIOPHARMA GLOBAL s. r. o
Represented by: Petr Novak	Represented by: Ing. Helena Rögnerová	Represented by: Pavel Marek